Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

French study checks if new combo works for mesothelioma in everyday practice

NCT ID NCT05308966

Knowledge-focused Sponsor: Groupe Francais De Pneumo-Cancerologie Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks back at 204 patients with untreated, inoperable malignant pleural mesothelioma who received a combination of two immunotherapy drugs, nivolumab and ipilimumab, through an early access program in France. Researchers will collect data from medical records to see how long patients lived without the cancer getting worse and track side effects. The goal is to confirm the benefits seen in an earlier clinical trial and support making this treatment more widely available.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
nivolumab and ipilimumab
What this could lead to
If successful, this study could confirm that the nivolumab-ipilimumab combination works well in real-world patients, supporting its wider use and reimbursement for mesothelioma.
What could go wrong
This is a retrospective observational study, not a controlled trial, so results may be less reliable. It only looks at patients already treated, and outcomes may vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

204 people

The number who actually took part.

Started

May 2022

Finished

Aug 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients with previously untreated and unresectable Malignant Pleural Mesothelioma treated with combination Nivolumab and Ipilimumab in the setting of the early access program not opposed to the collection of his/her data

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient with previously untreated and unresectable Malignant Pleural Mesothelioma treated with combination Nivolumab and Ipilimumab in the setting of the early access program * Patient enrolled in the French National Health Insurance program or with a third-party payer * Patient not opposed to the collection of his/her data (an information sheet will be to all living patients; for those who died, documented opposition to data collection in his/her medical file is not required) Exclusion Criteria: * Patient under curatorship or guardianship * Patient's explicit refusal to collect his / her data * Patients not managed at the investigating center and not followed by a center investigator

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Malignant pleural mesothelioma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer malignant pleural mesothelioma mesothelioma Mesothelioma, Malignant

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Malignant pleural mesothelioma Unresectable malignant neoplasm

Contacts and locations

Locations

  • CAC Mougins

    Mougins, 06250, France

  • CH Albi

    Albi, 81013, France

  • CH Annecy Genevois

    Pringy, 74374, France

  • CH Argenteuil

    Argenteuil, 95010, France

  • CH Avignon

    Avignon, 84000, France

  • CH Bastia

    Bastia, 20200, France

  • CH Bayonne

    Bayonne, 64100, France

  • CH Bligny

    Bligny, 91640, France

  • CH Cannes

    Cannes, 06400, France

  • CH Cornouaille

    Quimper, 02900, France

  • CH Dijon Bourgogne

    Dijon, 21000, France

  • CH Eure-Seine

    Évreux, 27015, France

  • CH Libourne

    Libourne, 33500, France

  • CH Nevers

    Nevers, 58000, France

  • CH St Quentin

    Saint-Quentin, 02321, France

  • CH Villefranche

    Villefranche-sur-Saône, 69400, France

  • CH Villeurbanne

    Villeurbanne, 69100, France

  • CH de Longjumeau

    Longjumeau, 91160, France

  • CH de Saint Malo

    St-Malo, 35400, France

  • CH du Cotentin

    Cherbourg, 50102, France

  • CH du Mans

    Le Mans, 72000, France

  • CHD les Oudaries

    La Roche-sur-Yon, 85000, France

  • CHITS Toulon Sainte Musse

    Toulon, 83056, France

  • CHRU Bretonneau

    Tours, 37044, France

  • CHU Angers

    Angers, 49033, France

  • CHU Besançon

    Besançon, 25000, France

  • CHU Caen

    Caen, 14033, France

  • CHU Hôpital Montpied

    Clermont-Ferrand, 63000, France

  • CHU La Mileterie

    Poitiers, 86021, France

  • CHU Lille

    Lille, 59000, France

  • CHU Morvan

    Brest, 29200, France

  • CHU Ponchailloux

    Rennes, 35000, France

  • CHU du Pays d'Aix

    Aix-en-Provence, 13616, France

  • Centre Antoine Lacassagne

    Nice, 06149, France

  • Centre Léon Bérard

    Lyon, 69373, France

  • Clinique Ambroise Paré

    Beuvry, 63660, France

  • Clinique Bordeaux

    Bordeaux, 33000, France

  • Clinique Gentilly

    Gentilly, 94250, France

  • Clinique Pasteur

    Brest, 29200, France

  • Clinique Saint Georges

    Nice, 06000, France

  • Clinique Saint Grégoire

    Rennes, 35000, France

  • Clinique de l'Estuaire

    Saint-Nazaire, 44600, France

  • GH Le Havre

    Le Havre, 76083, France

  • GH Paris Site St Joseph

    Paris, 75674, France

  • HIA Begin

    Saint-Mandé, 94160, France

  • HIA St Anne

    Toulon, 83800, France

  • Hôpital Ambroise Paré

    Boulogne-Billancourt, 92100, France

  • Hôpital Bichat

    Paris, 75018, France

  • Hôpital Charles Nicolle

    Rouen, 76031, France

  • Hôpital Cochin

    Paris, 75014, France

  • Hôpital Haut-Lévèque - Groupe Hospitalier SUD

    Pessac, 33604, France

  • Hôpital La Pitié-Salpêtrière

    Paris, 75651, France

  • Hôpital Larrey

    Toulouse, 31059, France

  • Hôpital Louis Pasteur

    Colmar, 68000, France

  • Hôpital Louis Pradel

    Bron, 69500, France

  • Hôpital Nord

    Marseille, 13915, France

  • Hôpital du Scorff

    Lorient, 56100, France

  • Hôpital privé de la Loire

    Saint-Etienne, 42100, France

  • IPC

    Marseille, 13009, France

  • Insititut de Cancerologie de l'Ouest

    Saint-Herblain, 44805, France

  • Institut Curie

    Paris, 75005, France

  • Les Hôpitaux Universitaires de Strasbourg

    Strasbourg, 76091, France

  • Unicancer

    Clermont-Ferrand, 63000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.